- $557.31m
- $554.58m
- $311.71m
Annual income statement for CorMedix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.191 | 0.065 | 0 | 43.5 | 312 |
| Cost of Revenue | |||||
| Gross Profit | 0.042 | 0.062 | 0 | 40.3 | 276 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 29.6 | 30.7 | 49 | 65.8 | 162 |
| Operating Profit | -29.4 | -30.6 | -49 | -22.4 | 150 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -29.5 | -30.3 | -46.3 | -19.3 | 150 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -28.2 | -29.7 | -46.3 | -17.9 | 163 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -28.2 | -29.7 | -46.3 | -17.9 | 163 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -28.2 | -29.7 | -46.3 | -17.9 | 163 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.749 | -0.737 | -0.91 | -0.305 | 2.03 |